Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide (AC2993) in T2DM patients on Sulfonylurea
NCT00039026Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2002
- Primary completion
- Aug 2003
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of exenatide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change in HbA1c at 30 weeks. Started Feb 2002; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00039026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00039026.